We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
QuantRx Biomedical Corporation (CE) | USOTC:QTXB | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.004 | 0.00 | 01:00:00 |
QUANTRX BIOMEDICAL CORPORATION
|
Nevada
|
|
33-0202574
|
(State or Other Jurisdiction of Incorporation or
Organization)
|
|
(I.R.S. Employer Identification Number)
|
10190
SW 90th Avenue, Tualatin, Oregon 97123
|
(Address of Principal Executive Offices) (Zip Code)
|
|
(212)
980-2235
|
(Registrant's Telephone Number, Including Area Code)
|
Large accelerated filer
|
[ ]
|
Accelerated filer
|
[ ]
|
Non-Accelerated filer
|
[X]
|
Smaller reporting company
|
[X]
|
|
|
Emerging growth company
|
[ ]
|
Title of each
class
|
Trading
Symbol(s)
|
Name of each
exchange on which registered
|
Common
Stock, par value $0.01 per share
|
QTXB
|
OTC:PINK
Marketplace
|
|
PAGE
|
|
|
|
|
1
|
||
|
|
|
|
2
|
|
|
|
|
|
3
|
|
|
|
|
|
4
|
|
|
|
|
|
5
|
|
|
|
|
|
6
|
|
|
|
|
12
|
||
|
|
|
15
|
||
|
|
|
|
|
|
16
|
||
|
||
16
|
||
|
||
16
|
||
|
||
16
|
||
|
||
16
|
||
|
||
16
|
||
|
||
16
|
||
|
|
|
17
|
|
For
the Three Months Ended June 30,
|
For
the Six Months Ended June 30,
|
||
|
2019
|
2018
|
2019
|
2018
|
Revenue:
|
|
|
|
|
Revenue:
|
$
-
|
$
-
|
$
-
|
$
-
|
Total
Revenue
|
-
|
-
|
-
|
-
|
|
|
|
|
|
Costs and Operating
Expense:
|
|
|
|
|
Sales, general and
administrative
|
16,784
|
47,517
|
39,363
|
75,497
|
Professional
fees
|
45,051
|
36,126
|
81,476
|
54,449
|
Total Costs and
Operating Expenses
|
61,835
|
83,643
|
120,839
|
129,946
|
|
|
|
|
|
LOSS FROM
OPERATIONS:
|
(61,835
)
|
(83,643
)
|
(120,839
)
|
(129,946
)
|
|
|
|
|
|
Other Income
(Expense):
|
|
|
|
|
Interest
Expense
|
(35,640
)
|
(59,371
)
|
(88,853
)
|
(118,286
)
|
Interest
Income
|
-
|
346
|
-
|
565
|
Total Other Income
(Expense), net
|
(35,640
)
|
(59,025
)
|
(88,853
)
|
(117,721
)
|
|
|
|
|
|
Profit (Loss)
Before Taxes
|
(97,475
)
|
(142,668
)
|
(209,692
)
|
(247,667
)
|
|
|
|
|
|
Provision for
Income Taxes
|
-
|
-
|
-
|
-
|
|
|
|
|
|
Net Profit
(Loss)
|
$
(97,475
)
|
$
(142,668
)
|
$
(209,692
)
|
$
(247,667
)
|
|
|
|
|
|
Basic and Diluted
Net Loss per Common Share
|
$
(0.00
)
|
$
(0.00
)
|
$
(0.00
)
|
$
(0.00
)
|
|
|
|
|
|
Basic and Diluted
Weighted Average Shares Used in per Share Calculation
|
78,696,461
|
78,696,461
|
78,696,461
|
78,696,461
|
|
For
the Six Months Ended June 30,
|
|
|
2019
|
2018
|
CASH FLOWS FROM OPERATING
ACTIVITIES
|
|
|
Net
loss
|
$
(209,692
)
|
$
(247,667
)
|
Adjustments to
reconcile net loss to net cash used by operating
activities:
|
|
|
Interest
earned on escrow account
|
-
|
(565
)
|
(Increase) Decrease
in:
|
|
|
Prepaid
expenses
|
20,510
|
18,773
|
Increase (Decrease)
in:
|
|
|
Accounts
Payable
|
2,321
|
(18,816
)
|
Accrued interest
and expenses
|
65,976
|
98,708
|
Net Cash Used by
Operating Activities
|
(120,885
)
|
(149,567
)
|
|
|
|
CASH FLOWS FROM INVESTING
ACTIVITIES
|
|
|
Net Cash Provided
by (Used in) Investing Activities
|
-
|
-
|
|
|
|
CASH FLOWS FROM FINANCING
ACTIVITIES
|
|
|
Repurchase of
preferred stock for cash
|
-
|
(20,000
)
|
Net Cash Provided
(Used) by Financing Activities
|
-
|
(20,000
)
|
|
|
|
Net Increase
(Decrease) in Cash and Cash Equivalents
|
(120,885
)
|
(169,567
)
|
|
|
|
Cash and Cash
Equivalents, Beginning of Period
|
322,024
|
460,111
|
|
|
|
Cash and Cash
Equivalents, End of Period
|
$
201,139
|
$
290,544
|
|
|
|
Supplemental Cash
Flow Disclosures:
|
|
|
Interest expense
paid in cash
|
$
763
|
$
524
|
Income tax
paid
|
$
-
|
$
-
|
|
Preferred Stock
|
Common
Stock
|
|
|
|
|
||
|
Amount
|
Number of Shares
|
Amount
|
Additional Paid-in Capital
|
Stock to be Issued
|
Accumulated Deficit
|
Total
|
|
For the three months ended June 30, 2018
|
|
|
|
|
|
|
|
|
Balance
at April 1, 2018
|
16,676,942
|
$
166,769
|
78,696,461
|
$
786,964
|
$
48,791,598
|
$
8,600
|
$
(50,608,482
)
|
$
(854,551
)
|
Repurchase
of preferred stock for cash
|
(10,480,049
)
|
(104,800
)
|
|
|
84,800
|
|
|
(20,000
)
|
Net
loss
|
-
|
-
|
-
|
-
|
-
|
-
|
(142,667
)
|
(142,667
)
|
Balance
at June 30, 2018
|
6,196,893
|
$
61,969
|
78,696,461
|
$
786,964
|
$
48,876,398
|
$
8,600
|
$
(50,751,149
)
|
$
(1,017,218
)
|
|
|
|
|
|
|
|
|
|
For the six months ended June 30, 2018
|
|
|
|
|
|
|
|
|
Balance
at January 1, 2018
|
16,676,942
|
$
166,769
|
78,696,461
|
$
786,964
|
$
48,791,598
|
$
8,600
|
$
(50,503,482
)
|
$
(749,551
)
|
Repurchase
of preferred stock for cash
|
(10,480,049
)
|
(104,800
)
|
-
|
-
|
84,800
|
-
|
-
|
(20,000
)
|
Net
loss
|
-
|
-
|
-
|
-
|
-
|
-
|
(247,667
)
|
(247,667
)
|
Balance
at June 30, 2018
|
6,196,893
|
$
61,969
|
78,696,461
|
$
786,964
|
$
48,876,398
|
$
8,600
|
$
(50,751,149
)
|
$
(1,017,218
)
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, 2019
|
|
|
|
|
|
|
|
|
Balance
at April 1, 2019
|
6,196,893
|
$
61,969
|
78,696,461
|
$
786,964
|
$
48,876,398
|
$
8,600
|
$
(51,352,549
)
|
$
(1,618,618
)
|
Net
loss
|
-
|
-
|
-
|
-
|
-
|
-
|
(97,475
)
|
(97,475
)
|
Balance
at June 30, 2019
|
6,196,893
|
$
61,969
|
78,696,461
|
$
786,964
|
$
48,876,398
|
$
8,600
|
$
(51,450,024
)
|
$
(1,716,093
)
|
|
|
|
|
|
|
|
|
|
For the six months ended June 30, 2019
|
|
|
|
|
|
|
|
|
Balance
at January 1, 2019
|
6,196,893
|
$
61,969
|
78,696,461
|
$
786,964
|
$
48,876,398
|
$
8,600
|
$
(51,240,332
)
|
$
(1,506,401
)
|
Net
loss
|
|
|
|
|
|
|
(209,692
)
|
(209,692
)
|
Balance
at June 30, 2019
|
6,196,893
|
$
61,969
|
78,696,461
|
$
786,964
|
$
48,876,398
|
$
8,600
|
$
(51,450,024
)
|
$
(1,716,093
)
|
|
June 30,
2019
|
December 31,
2018
|
Notes
Payable and accrued interest payable
|
$
1,951,218
|
$
1,870,685
|
Notes
Payable and accrued interest payable, related party
|
143,286
|
135,728
|
Total
notes payable
|
$
2,094,504
|
$
2,006,413
|
Exhibit
|
|
Description
|
|
Certification of Chief Executive Officer and Principal Financial
and Accounting Officer required under Rule 13a-14(a) or Rule
15d-14(a) of the Securities and Exchange Act of 1934, as
amended.
|
|
|
Certification of Chief Executive Officer and Principal Financial
and Accounting Officer required under Rule 13a-14(a) or Rule
15d-14(a) of the Securities and Exchange Act of 1934, as amended,
and 18 U.S.C. Section 1350.
|
|
101.INS
|
|
XBRL Instance Document
|
101.SCH
|
|
XBRL Taxonomy Extension Schema
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase
|
Date: August 15, 2019
|
/s/
Shalom Hirschman
|
|
Shalom Hirschman
Principal Executive, Financial and Accounting Officer
|
1 Year QuantRx Biomedical (CE) Chart |
1 Month QuantRx Biomedical (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions